Klebsiella pneumoniae Infections (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2021, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 36 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

ABAC Therapeutics SA

AEON Medix Inc

Affinivax Inc

Akthelia Pharmaceuticals Ltd

Appili Therapeutics Inc

Armata Pharmaceuticals

BB200 LLC

Bioversys AG

Bugworks Research India Pvt Ltd

Celdara Medical LLC

CHO Pharma Inc

Clarametyx Biosciences Inc

ContraFect Corp

Dong-A ST Co Ltd

EnBiotix Inc

F. Hoffmann-La Roche Ltd

Fedora Pharmaceuticals Inc

Forge Therapeutics Inc

GlaxoSmithKline Plc

LimmaTech Biologics AG

Linnaeus Bioscience Inc

Melinta Therapeutics Inc

Microbiotix Inc

Mikrobiomik Healthcare Company SL

Neoculi Pty Ltd

Nosopharm SAS

Oryn Therapeutics

Pedanius Therapeutics Ltd

Peptilogics Inc

Phico Therapeutics Ltd

Planet Biotechnology Inc

ReAlta Life Sciences Inc

Recce Pharmaceuticals Ltd

RemAb Therapeutics SL

Shionogi & Co Ltd

Soligenix Inc

Spero Therapeutics Inc

Summit Therapeutics Ltd

Syntiron LLC

Taisho Pharmaceutical Holdings Co Ltd

Techulon Inc

VaxNewMO LLC

Vaxxilon AG

Venus Medicine Research Centre

Table of Contents

Table of Contents

Introduction

Klebsiella pneumoniae Infections - Overview

Klebsiella pneumoniae Infections - Therapeutics Development

Klebsiella pneumoniae Infections - Therapeutics Assessment

Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development

Klebsiella pneumoniae Infections - Drug Profiles

Klebsiella pneumoniae Infections - Dormant Projects

Klebsiella pneumoniae Infections - Discontinued Products

Klebsiella pneumoniae Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Klebsiella pneumoniae Infections – Pipeline by ABAC Therapeutics SA, 2021

Klebsiella pneumoniae Infections – Pipeline by AEON Medix Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Affinivax Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Akthelia Pharmaceuticals Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Appili Therapeutics Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Armata Pharmaceuticals, 2021

Klebsiella pneumoniae Infections – Pipeline by BB200 LLC, 2021

Klebsiella pneumoniae Infections – Pipeline by Bioversys AG, 2021

Klebsiella pneumoniae Infections – Pipeline by Bugworks Research India Pvt Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Celdara Medical LLC, 2021

Klebsiella pneumoniae Infections – Pipeline by CHO Pharma Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Clarametyx Biosciences Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by ContraFect Corp, 2021

Klebsiella pneumoniae Infections – Pipeline by Dong-A ST Co Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by EnBiotix Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Fedora Pharmaceuticals Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Forge Therapeutics Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by GlaxoSmithKline Plc, 2021

Klebsiella pneumoniae Infections – Pipeline by LimmaTech Biologics AG, 2021

Klebsiella pneumoniae Infections – Pipeline by Linnaeus Bioscience Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Melinta Therapeutics Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Microbiotix Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Mikrobiomik Healthcare Company SL, 2021

Klebsiella pneumoniae Infections – Pipeline by Neoculi Pty Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Nosopharm SAS, 2021

Klebsiella pneumoniae Infections – Pipeline by Oryn Therapeutics, 2021

Klebsiella pneumoniae Infections – Pipeline by Pedanius Therapeutics Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Peptilogics Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Phico Therapeutics Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Planet Biotechnology Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by ReAlta Life Sciences Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Recce Pharmaceuticals Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by RemAb Therapeutics SL, 2021

Klebsiella pneumoniae Infections – Pipeline by Shionogi & Co Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Soligenix Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Spero Therapeutics Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by Summit Therapeutics Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Syntiron LLC, 2021

Klebsiella pneumoniae Infections – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021

Klebsiella pneumoniae Infections – Pipeline by Techulon Inc, 2021

Klebsiella pneumoniae Infections – Pipeline by VaxNewMO LLC, 2021

Klebsiella pneumoniae Infections – Pipeline by Vaxxilon AG, 2021

Klebsiella pneumoniae Infections – Pipeline by Venus Medicine Research Centre, 2021

Klebsiella pneumoniae Infections – Dormant Projects, 2021

Klebsiella pneumoniae Infections – Dormant Projects, 2021 (Contd..1)

Klebsiella pneumoniae Infections – Dormant Projects, 2021 (Contd..2)

Klebsiella pneumoniae Infections – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports